-

Viz.ai Wins 2025 Edison Award™ for Machine Learning Innovation for the Third Consecutive Year

Honored for excellence and innovation in cardiovascular health diagnostics for Viz HCM module

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has been named an Award Winner in the 2025 Edison Awards, for the third year in a row. Viz HCM, the company’s AI software solution designed to detect and triage patients with signs of hypertrophic cardiomyopathy (HCM), was recognized in the Health Medical & Biotech category and Cardiovascular Health Diagnostics and Monitoring subcategory. The Edison Awards, named after the American inventor Thomas Alva Edison, honor excellence in new product and service development, marketing, design and innovation. The awards are widely recognized as one of the premier accolades that companies can receive in the name of innovation and business success.

“We are honored to win our third, prestigious Edison Award, reaffirming our mission-critical work to transform AI-driven healthcare,” said Dr. Chris Mansi, CEO and co-founder of Viz.ai. “HCM is an underdiagnosed condition that is the most commonly inherited cardiac disease, yet, unfortunately only 15% of these patients are diagnosed. The recognition of Viz HCM, which accelerates the patient identification and journey for this serious disease, validates our efforts to help clinicians to deliver faster and better care.”

Viz HCM uses artificial intelligence to analyze all 12-lead electrocardiograms (ECGs) from across a health system to identify suspected HCM cases, notify cardiology care teams and increase the likelihood that patients get the right follow-up and diagnosis. The Viz HCM module, developed as part of a multi-year funding agreement between Viz.ai and Bristol Myers Squibb (NYSE:BMY), was granted De Novo approval by the FDA in August 2023, creating a new regulatory category for cardiovascular machine learning-based notification software. Recent data, presented at the American College of Cardiology meeting, demonstrated that Viz HCM successfully helped identify 574 HCM patients in a single major academic hospital (Cleveland Clinic) in a 9 month period, highlighting Viz HCM’s ability for more effective disease detection.1

All nominations are reviewed by the Edison Awards’ Steering Committee and an executive judging body. The panel is composed of more than 2,000 senior business executives and academics from the fields of product development, design, engineering, science, marketing and education, as well as past winners.

Winners were announced at the Edison Awards Gala on April 3, 2025 in Fort Myers, FL.

For more information on Viz HCM, please visit https://www.viz.ai/hypertrophic-cardiomyopathy.

1 Real-World Artificial Intelligence–Based Electrocardiographic Analysis to Diagnose Hypertrophic Cardiomyopathy. JACC: Clinical Electrophysiology. https://www.jacc.org/doi/10.1016/j.jacep.2025.02.024

About Viz.ai

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,700+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One® is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit Viz.ai.

About The Edison Awards

Established in 1987, the Edison Awards are dedicated to recognizing, honoring and fostering innovations and innovators. Named after Thomas Alva Edison (1847-1931), the annual competition honors excellence in new product and service development, marketing, human-centered design and innovation. Past award recipients include Jony Ive, Martha Stewart, Carmichael Roberts and companies leading in innovation including; Nest, now part of Google, AMD, Intel, Naqi, 3M and Cargill. In 2021, the Edison Awards introduced the inaugural Lewis Latimer Fellowship program designed to celebrate, connect and bring together a community of innovative Black thought leaders. For more information, visit www.edisonawards.com.

Contacts

Media Contact
Carolyn Jones
carolyn.jones@viz.ai

Daniel Yunger
daniel.yunger@kekstcnc.com

Viz.ai


Release Versions

Contacts

Media Contact
Carolyn Jones
carolyn.jones@viz.ai

Daniel Yunger
daniel.yunger@kekstcnc.com

Social Media Profiles
More News From Viz.ai

New Data Show Viz.ai’s AI-Enabled ECG Screening Increases Detection and Accelerates Diagnosis of Hypertrophic Cardiomyopathy

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data demonstrating how Viz HCM enables faster, accurate detection of hypertrophic cardiomyopathy (HCM), to help ensure that more patients are identified. Two studies, which will be presented at the American Heart Association (AHA) Scientific Sessions 2025, show Viz.ai’s real-world ability to identify more patients with HCM years earlier than current...

Viz.ai Launches Viz Assist: The First Multimodal AI Agent Platform for Faster Treatment and Better Outcomes

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz Assist™, a suite of autonomous AI agents that significantly enhance how care teams identify, prioritize, and act on critical patient data.1 Viz Assist marks a major step forward in Viz.ai’s mission to use technology to reduce time to treatment and improve patient outcomes. Viz Assist incorporates inputs from ambient listening and the electronic...

Viz.ai Launches Viz ACS™ to Accelerate Treatment for Heart Attack and Reduce Unnecessary Activations

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz ACS, a new solution in the Viz Cardio™ Suite. Designed to unite the acute coronary syndrome (ACS) care team on a single platform, Viz ACS provides Emergency Department (ED) physicians and cardiologists with the same high-quality ECGs and patient data in real time. This streamlined workflow can help improve communication, speeds treatment, and re...
Back to Newsroom